Skip to main content Accessibility help
×
Home
  • Print publication year: 2020
  • Online publication date: May 2020

Chapter 5 - Pharmacogenomics and Psychopharmacology

from Part 1 - Basic Science and General Principles

Summary

While genome-wide association analysis and related multi-omic strategies have in recent years dominated the field of complex disorders including mental health and addictions, in pharmacogenomics, drug metabolizing enzymes show Mendelian patterns of inheritance with correspondingly large effect sizes. Consistent with this, genes encoding these enzymes make up the majority of the genes for which the strength of the association with clinical effect of psychiatric medications is sufficient to recommend clinical utility (Bousman et al., 2018). Moreover, such enzymes are expressed in the brain (Aitchison et al., 2010; Kalow & Tyndale, 1992). We herein provide a comprehensive review of the relevance of drug metabolizing enzyme and transporter genes to mental health and addictions.

Related content

Powered by UNSILO
Abernethy, DR, Todd, EL (1985). Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol, 28(4), 425428.
Adali, O, Carver, GC, Philpot, RM (1998). Modulation of human flavin-containing monooxygenase 3 activity by tricyclic antidepressants and other agents: importance of residue 428. Arch Biochem Biophys, 358(1), 9297. doi:10.1006/abbi.1998.0835.
Ahmed, I, Dagincourt, PG, Miller, LG, Shader, RI (1993). Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry, 38(1), 6263.
Aitchison, KJ (2003). Pharmacogenetic studies of CYP2D6, CYP2C19, and CYP1A2, and investigation of their role in clinical response to antipsychotics and antidepressants. Unpublished PhD thesis, King’s College London.
Aitchison, KJ, Munro, J, Wright, P, et al. (1999). Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol, 48(3), 388394.
Aitchison, KJ, Gonzalez, FJ, Quattrochi, LC, et al. (2000a). Identification of novel polymorphisms in the 5’ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics, 10(8), 695704.
Aitchison, KJ, Jann, MW, Zhao, JH, et al. (2000b). Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J Psychopharmacol, 14(4), 353359. doi:10.1177/026988110001400403.
Aitchison, KJ, Jordan, BD, Sharma, T (2000c). The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis. Drug Metabol Drug Interact, 16(1), 1538.
Aitchison, KJ, Bienroth, M, Cookson, J, et al. (2009). A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol, 23(3), 231240. doi:10.1177/0269881108098820.
Aitchison, KJ, Datla, K, Rooprai, H, Fernando, J, Dexter, D (2010). Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration. J Psychopharmacol, 24(8), 12611268. doi:10.1177/0269881109105789.
Aklillu, E, Persson, I, Bertilsson, L, et al. (1996). Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther, 278(1), 441446.
Aklillu, E, Kalow, W, Endrenyi, L, et al. (2007). CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics, 17(11), 989993. doi:10.1097/FPC.0b013e3282f01aa3.
Aller, SG, Yu, J, Ward, A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 323(5922), 17181722. doi:10.1126/science.1168750.
Altman, RB, Whirl-Carrillo, M, Klein, TE (2013). Challenges in the pharmacogenomic annotation of whole genomes. Clin Pharmacol Ther, 94(2), 211213. doi:10.1038/clpt.2013.111.
American Psychiatric Association (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. Available at: https://psychiatryonline.org/guidelines (last accessed 5.12.18).
Arici, M, Özhan, G (2017). The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J, 25(2), 294297. doi:10.1016/j.jsps.2016.06.001.
Aronow, WS, Shamliyan, TA (2018). Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med, 6(8), 147. doi:10.21037/atm.2018.03.17.
Asberg, M, Crönholm, B, Sjöqvist, F, Tuck, D (1971). Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J, 3(5770), 331334.
Assenat, E, Gerbal-Chaloin, S, Larrey, D, et al. (2004). Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology, 40(4), 951960. doi:10.1002/hep.20387.
Axelrod, J (1957). O-Methylation of epinephrine and other catechols in vitro and in vivo. Science, 126(3270), 400401. doi:10.1126/science.126.3270.400.
Ayesh, R, Mitchell, SC, Zhang, A, Smith, RL (1993). The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ, 307(6905), 655657.
Azuma, J, Hasunuma, T, Kubo, M, et al. (2012). The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol, 68(1), 2937.
Bajpai, M, Roskos, LK, Shen, DD, Levy, RH (1996). Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos, 24(12), 14011403.
Balant-Gorgia, AE, Balant, LP, Garrone, G (1989). High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit, 11(4), 415420.
Baltenberger, EP, Buterbaugh, WM, Martin, BS, Thomas, CJ (2015). Review of antidepressants in the treatment of neuropathic pain. Ment Health Clin, 5(3), 123133.
Baririan, N, Horsmans, Y, Desager, JP, et al. (2005). Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol, 45(12), 14341441. doi:10.1177/0091270005282629.
Bauer, B, Hartz, AM, Fricker, G, Miller, DS (2004). Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol, 66(3), 413419. doi:10.1124/mol.66.3.
Beedham, C (1997). The role of non-P450 enzymes in drug oxidation. Pharm World Sci, 19(6), 255263.
Bertilsson, L (1995). Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet, 29(3), 192209. doi:10.2165/00003088-199529030-00005.
Bertilsson, L, Aberg-Wistedt, A (1983). The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol, 15(3), 388390.
Bertilsson, L, Dahl, ML (1996). Polymorphic drug oxidation – relevance to the treatment of psychiatric disorders. CNS Drugs, 5(3), 200223. doi:10.2165/00023210–199605030–00006.
Bertilsson, L, Mellstrom, B, Sjokvist, F, Martenson, B, Asberg, M (1981). Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet, 1(8219), 560561.
Bertilsson, L, Dahl, ML, Ekqvist, B, Llerena, A (1993a). Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol Ser, 10, 230237.
Bertilsson, L, Dahl, ML, Sjoqvist, F, et al. (1993b). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341(8836), 63.
Bertilsson, L, Dahl, ML, Dalen, P, Al-Shurbaji, A (2002). Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol, 53(2), 111122.
Bhaskar, LV, Thangaraj, K, Patel, M, et al. (2013). EPHX1 gene polymorphisms in alcohol dependence and their distribution among the Indian populations. Am J Drug Alcohol Abuse, 39(1), 1622. doi:10.3109/00952990.2011.643991.
Bigos, KL, Bies, RR, Pollock, BG, et al. (2011). Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry, 16(6), 620625. doi:10.1038/mp.2011.38.
Blake, CM, Kharasch, ED, Schwab, M, Nagele, P (2013). A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther, 94(3), 394399. doi:10.1038/clpt.2013.96.
Bloomer, JC, Woods, FR, Haddock, RE, Lennard, MS, Tucker, GT (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol, 33(5), 521523.
Boland, MR, Tatonetti, NP (2016). Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review. Pharmacogenomics J, 16(5), 411429. doi:10.1038/tpj.2016.48.
Boobis, AR, Lynch, AM, Murray, S, et al. (1994). CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res, 54(1), 8994.
Bourin, M, Chue, P, Guillon, Y (2001). Paroxetine: a review. CNS Drug Rev, 7(1), 2547.
Bousman, CA, Hopwood, M (2016). Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry, 3(6), 585590. doi:10.1016/S2215-0366(16)00017-1.
Bousman, C, Allen, J, Eyre, HA (2018). Pharmacogenetic tests in psychiatry. Am J Psychiatry, 175(2), 189. doi:10.1176/appi.ajp.2017.17101086.
Bousman, C, Maruf, AA, Muller, DJ (2019). Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry, 32(1), 715. doi:10.1097/YCO.0000000000000465.
Bradford, LD (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3(2), 229243. doi:10.1517/14622416.3.2.229.
Brøsen, K (1993). The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig, 71(12), 10021009.
Brøsen, K, Skjelbo, E, Rasmussen, BB, Poulsen, HE, Loft, S (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol, 45(6), 12111214.
Browning, SL, Tarekegn, A, Bekele, E, Bradman, N, Thomas, MG (2010). CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics, 20(11), 647664. doi:10.1097/FPC.0b013e32833e90eb.
Bruyere, A, Decleves, X, Bouzom, F, et al. (2010). Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm, 7(5), 15961607. doi:10.1021/mp100015x.
Bu, HZ (2006). A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr Drug Metab, 7(3), 231249.
Caruso, A, Bellia, C, Pivetti, A, et al. (2014). Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients. Pharmgenomics Pers Med, 7, 117120. doi:10.2147/PGPM.S55548.
Carvajal, FJ, Inestrosa, NC (2011). Interactions of AChE with Aβ aggregates in Alzheimer’s brain: therapeutic relevance of IDN 5706. Front Mol Neurosci, 4, 19. doi:10.3389/fnmol.2011.00019.
Cascorbi, I (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol, 201, 261283. doi:10.1007/978-3-642-14541-4_6.
Cashman, JR, Zhang, J (2002). Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos, 30(10), 10431052.
Caspi, A, Moffitt, TE, Cannon, M, et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry, 57(10), 11171127. doi:10.1016/j.biopsych.2005.01.026.
Caudle, KE, Klein, TE, Hoffman, JM, et al. (2014). Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab, 15(2), 209217.
Caudle, KE, Gammal, RS, Whirl-Carrillo, M, et al. (2016). Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm, 73(23), 19771985. doi:10.2146/ajhp150977.
Chen, J-T, Wei, L, Chen, T-L, Huang, C-J, Chen, R-M (2018). Regulation of cytochrome P450 gene expression by ketamine: a review. Expert Opin Drug Metab Toxicol, 14(7), 709720.
Chen, S, Chou, WH, Blouin, RA, et al. (1996). The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther, 60(5), 522534. doi:10.1016/S0009-9236(96)90148-4.
Chen, Y, Zane, NR, Thakker, DR, Wang, MZ (2016). Quantification of flavin-containing monooxygenases 1, 3, and 5 in human liver microsomes by UPLC-MRM-based targeted quantitative proteomics and its application to the study of ontogeny. Drug Metab Dispos, 44(7), 975983. doi:10.1124/dmd.115.067538.
Chou, WH, Yan, FX, Robbins-Weilert, DK, et al. (2003). Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem, 49(4), 542551.
Christensen, M, Tybring, G, Mihara, K, et al. (2002). Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther, 71(3), 141152. doi:10.1067/mcp.2002.121788.
Chung, WH, Hung, SI, Hong, HS, et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 428(6982), 486. doi:10.1038/428486a.
Coleman, T, Ellis, SW, Martin, IJ, Lennard, MS, Tucker, GT (1996). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 – implications for susceptibility to Parkinson’s disease. J Pharmacol Exp Ther, 277(2), 685690.
Coller, JK, Krebsfaenger, N, Klein, K, et al. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol, 54(2), 157167. doi:10.1046/j.1365-2125.2002.01614.x.
Committee on Safety of Medicines-Medicines Control Agency (1995). Cardiac arrhythmias with pimozide (Orap). Curr Probl Pharmacovigilance, 21, 1.
Consoli, G, Lastella, M, Ciapparelli, A, et al. (2009). ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics, 10(8), 12671276. doi:10.2217/pgs.09.51.
Cornelis, MC, El-Sohemy, A, Kabagambe, EK, Campos, H (2006). Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA, 295(10), 11351141. doi:10.1001/jama.295.10.1135.
Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14(2), 119136. doi:10.1002/wps.20204.
Crespi, CL, Penman, BW, Leakey, JAE, et al. (1990). Human cytochrome P450IIA3: cDNA sequence role of the enzyme in the metabolic activation of promutagens comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis, 11(8), 12931300.
Crews, KR, Gaedigk, A, Dunnenberger, HM, et al; Clinical Pharmacogenetics Implementation Consortium. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther, 95(4), 376382. doi:10.1038/clpt.2013.254.
Cupp, MJ, Tracy, TS (1998). Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician, 57(1), 107116.
Cusack, B, Nelson, A, Richelson, E (1994). Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl), 114(4), 559565.
Czekaj, P (2000). Phenobarbital-induced expression of cytochrome P450 genes. Acta Biochim Pol, 47(4), 10931105.
Czekaj, P, Skowronek, R (2012). Transcription factors potentially involved in regulation of cytochrome P450 gene expression. In Paxton, J, ed., Topics on Drug Metabolism. Croatia: InTech, pp. 171190.
Daci, A, Beretta, G, Vllasaliu, D, et al. (2015). Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLoS One, 10(11), e0142408. doi:10.1371/journal.pone.0142408.
Dahl-Puustinen, M-L, Lidén, A, Alm, C, Nordin, C, Bertilsson, L (1989). Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther, 46(1), 7881.
Dalen, P, Dahl, ML, Bernal Ruiz, ML, Nordin, J, Bertilsson, L (1998). 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther, 63(4), 444452. doi:10.1016/S0009-9236(98)90040-6.
Dannenberg, LO, Edenberg, HJ (2006). Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics, 7, 181. doi:10.1186/1471-2164-7-181.
de Andrés F, Sosa-Macías, M, Llerena, A (2014). A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity. Bioanalysis, 6(5), 683696. doi:10.4155/bio.14.20.
de Klerk, OL, Nolte, IM, Bet, PM, et al. (2013). ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J, 13(4), 349353. doi:10.1038/tpj.2012.16.
de Leon, J (2009). The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res, 59(2), 8189. doi:10.1016/j.phrs.2008.10.002.
de Morais, SM, Wilkinson, GR, Blaisdell, J, et al. (1994). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem, 269(22), 1541915422.
Del Tredici, AL, Malhotra, A, Dedek, M, et al. (2018). Frequency of CYP2D6 alleles including structural variants in the United States. Front Pharmacol, 9, 305. doi:10.3389/fphar.2018.00305.
DeLeon, A, Patel, NC, Crismon, ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther, 26(5), 649666.
Desta, Z, Kerbusch, T, Soukhova, N, et al. (1998). Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther, 285(2), 428437.
Desta, Z, Kerbusch, T, Flockhart, DA (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther, 65(1), 1020. https://doi.org/10.1016/S0009-9236(99)70117-7.
Desta, Z, Zhao, X, Shin, JG, Flockhart, DA (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet, 41(12), 913958. doi:10.2165/00003088-200241120-00002.
Desta, Z, Saussele, T, Ward, B, et al. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics, 8(6), 547558. doi:10.2217/14622416.8.6.547.
di Iulio, J, Fayet, A, Arab-Alameddine, M, et al.; Swiss HIV Cohort Study (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics, 19(4), 300309. doi:10.1097/FPC.0b013e328328d577.
Dobrinas, M, Cornuz, J, Oneda, B, et al. (2011). Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther, 90(1), 117125. doi:10.1038/clpt.2011.70.
Doring, B, Petzinger, E (2014). Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev, 46(3), 261282. doi:10.3109/03602532.2014.882353.
Drolet, B, Rousseau, G, Daleau, P, et al. (2001). Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther, 6(3), 255260. doi:10.1177/107424840100600306.
Drozda, K, Müller, DJ, Bishop, JR (2014). Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy, 34(2), 166184. doi:10.1002/phar.1398.
Eaton, DL, Gallagher, EP, Bammler, TK, Kunze, KL (1995). Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 5(5), 259274.
Ehlert, FJ, Delen, FM, Yun, SH, Liem, HA (1990). The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther, 253(1), 1319.
Eichelbaum, M (1984). Polymorphic drug oxidation in humans. Fed Proc, 43(8), 22982302.
Ekroos, M, Sjogren, T (2006). Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A, 103(37), 1368213687. doi:10.1073/pnas.0603236103.
El-Sherbeni, AA, El-Kadi, AO (2014). The role of epoxide hydrolases in health and disease. Arch Toxicol, 88(11), 20132032. doi:10.1007/s00204-014-1371-y.
Elsinga, PH, Hendrikse, NH, Bart, J, Vaalburg, W, van Waarde, A (2004). PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des, 10(13), 14931503.
Eriksson, N, Wadelius, M (2012). Prediction of warfarin dose: why, when and how? Pharmacogenomics, 13(4), 429440. doi:10.2217/pgs.11.184.
Espinoza, M, Rivero Osimani, V, Sánchez, V, Rosenbaum, E, Guiñazú, N. (2016). B-esterase determination and organophosphate insecticide inhibitory effects in JEG-3 trophoblasts. Toxicol In Vitro, 32, 190197. doi:10.1016/j.tiv.2016.01.001.
Fabbri, C, Tansey, KE, Perlis, RH, et al. (2018). Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol, 28(8), 945954. doi:10.1016/j.euroneuro.2018.05.009.
Fan, WL, Shiao, MS, Hui, RC, et al. (2017). HLA association with drug-induced adverse reactions. J Immunol Res, 2017, 3186328. doi:10.1155/2017/3186328.
Fang, H, Xu, X, Kaur, K, et al. (2019). A screening test for HLA-B( *)15:02 in a large United States patient cohort identifies broader risk of carbamazepine-induced adverse events. Front Pharmacol 10, 149.
Feng, J, Sun, J, Wang, MZ, et al. (2010). Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual’s drug responses. Pharmacogenomics, 11(10), 14031425. doi:10.2217/pgs.10.99.
Ferrell, PB, McLeod, HL (2008). Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics, 9(10), 15431546. doi:10.2217/14622416.9.10.1543.
Fiore, MC, Jorenby, DE, Schensky, AE, et al. (1995). Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clin Proc, 70(3), 209213. doi:10.1016/S0025-6196(11)64939-2.
Flockhart, DA, Drici, MD, Kerbusch, T, et al. (2000). Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol, 20(3), 317324.
Foti, RS, Dalvie, DK (2016). Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics. Drug Metab Dispos, 44(8), 12291245. doi:10.1124/dmd.116.071753.
Foti, RS, Wienkers, LC, Wahlstrom, JL (2010). Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen, 13(2), 145158.
Fricke-Galindo, I, LLerena, A, Jung-Cook, H, López-López, M (2018). Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol, 11(7), 705718. doi:10.1080/17512433.2018.1486707.
Fromm, MF, Kim, RB (2011). Drug Transporters: Handbook of Experimental Pharmacology v. 201. Available at: http://dx.doi.org/10.1007/978–3-642–14541-4 (last accessed 5.12.18).
Fuhr, U, Anders, EM, Mahr, G, Sorgel, F, Staib, AH (1992). Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother, 36(5), 942948.
Fuhr, U, Klittich, K, Staib, AH (1993). Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol, 35(4), 431436.
Fuhr, U, Jetter, A, Kirchheiner, J (2007). Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ‘cocktail’ approach. Clin Pharmacol Ther, 81, 270283.
Fujita, K, Sasaki, Y (2007). Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab, 8(6), 554562.
Fukami, T, Yokoi, T (2012). The emerging role of human esterases. Drug Metab Pharmacokinet, 27(5), 466477.
Fulop, G, Phillips, RA, Shapiro, AK, et al. (1987). ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry, 144(5), 673675. doi:10.1176/ajp.144.5.673.
Furnes, B, Feng, J, Sommer, SS, Schlenk, D (2003). Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos, 31(2), 187193.
Genaro-Mattos, TC, Tallman, KA, Allen, LB, et al. (2018). Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. Toxicol Appl Pharmacol, 349, 2128. doi:10.1016/j.taap.2018.04.029.
Ghodke-Puranik, Y, Thorn, CF, Lamba, JK, et al. (2013). Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics, 23(4), 236241. doi:10.1097/FPC.0b013e32835ea0b2.
Ghotbi, R, Christensen, M, Roh, HK, et al. (2007). Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol, 63(6), 537546. doi:10.1007/s00228-007-0288-2.
Goh, BC, Lee, SC, Wang, LZ, et al. (2002). Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol, 20(17), 36833690. doi:10.1200/JCO.2002.01.025.
Goldman, D (2014). Roles of COMT, NPY and GCH1 in acute and chronic pain/stress response. Mol Pain, 10(Suppl 1), O5. doi:10.1186/1744-8069-10-S1-O5.
Goldman, D, Weinberger, DR, Malhotra, AK, Goldberg, TE (2009). The role of COMT Val158Met in cognition. Biol Psychiatry, 65(1), e1e2; author reply e3–e4. doi:10.1016/j.biopsych.2008.07.032.
Goldstein, JA, de Morais, SM (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4(6), 285299.
Gong, QL, Hedner, T, Hedner, J, Bjorkman, R, Nordberg, G (1991). Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol, 193(1), 4756.
Gonzalez, FJ, Gelboin, HV (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev, 26(1–2), 165183.
Goodarzi, MO, Xu, N, Azziz, R (2008). Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 93(7), 29092912. doi:10.1210/jc.2008-0403.
Gough, AC, Miles, JS, Spurr, NK, et al. (1990). Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347(6295), 773776. doi:10.1038/347773a0.
Gram, LF, Kragh-Sorensen, P, Kristensen, CB, et al. (1984). Plasma level monitoring of antidepressants: theoretical basis and clinical application. Adv Biochem Psychopharmacol, 39, 399411.
Grisaru, D, Sternfeld, M, Eldor, A, Glick, D, Soreq, H (1999). Structural roles of acetylcholinesterase variants in biology and pathology. Eur J Biochem, 264(3), 672686.
Grossberg, GT (2003). Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on. Curr Ther Res Clin Exp, 64(4), 216235. doi:10.1016/S0011-393X(03)00059-6.
Guengerich, FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 117. doi:10.1146/annurev.pharmtox.39.1.1.
Haas, DW, Ribaudo, HJ, Kim, RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS, 18(18), 23912400.
Haberl, M, Anwald, B, Klein, K, et al. (2005). Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics, 15(9), 609624.
Haddock, RE, Johnson, AM, Langley, PF, et al. (1989). Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand, 80(S350), 2426.
Hadidi, H, Zahlsen, K, Idle, JR, Cholerton, S (1997). A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol, 35(9), 903907.
Hals, P-A, Hall, H, Dahl, SG (1986). Phenothiazine drug metabolites: dopamine D2 receptor, α1-and α2-adrenoceptor binding. Eur J Pharmacol, 125(3), 373381.
Hammons, GJ, Milton, D, Stepps, K, et al. (1997). Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis, 18(4), 851854.
Hanioka, N, Kimura, S, Meyer, UA, Gonzalez, FJ (1990). The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet, 47(6), 9941001.
Hansen, LB (1981). The clinical significance of measuring perphenazine in plasma during oral antipsychotic treatment. In Usdin, E, Dahl, SG, Gram, LF, Lingjærde, O, eds., Clinical Pharmacology in Psychiatry – Neuroleptic and Antidepressant Research. London: Macmillan, pp. 211216.
Hansen, LB, Larsen, NE (1983). Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects. In Gram, LF, Usdin, E, Dahl, SG, et al., eds., Clinical Pharmacology in Psychiatry – Bridging the Experimental-Therapeutic Gap. London: Macmillan, pp. 175181.
Hansen, LB, Larsen, NE (1985). Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berl), 87(1), 1619.
Hansen, LB, Elley, J, Christensen, TR, et al. (1979). Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol, 7(1), 7580.
Hansen, LB, Larsen, NE, Gulmann, N. (1982). Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl), 78(2), 112115.
Hartsfield, JK Jr, Sutcliffe, MJ, Everett, ET, et al. (1998). Assignment1 of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization. Cytogenet Cell Genet, 83(1–2), 4445. doi:10.1159/000015164.
Hasin, Y, Avidan, N, Bercovich, D, et al. (2005). Analysis of genetic polymorphisms in acetylcholinesterase as reflected in different populations. Curr Alzheimer Res, 2(2), 207218.
Hassett, C, Robinson, KB, Beck, NB, Omiecinski, CJ (1994). The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization. Genomics, 23(2), 433442. doi:10.1006/geno.1994.1520.
Hemeryck, A, Belpaire, FM (2002). Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab, 3(1), 1337.
Hendset, M, Molden, E, Knape, M, Hermann, M (2014). Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit, 36(1), 8085. doi:10.1097/FTD.0000000000000018.
Herrlin, K, Yasui-Furukori, N, Tybring, G, et al. (2003). Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol, 56(4), 415421.
Hesse, LM, He, P, Krishnaswamy, S, et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics, 14(4), 225238.
Hicks, JK, Swen, JJ, Thorn, CF, et al. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther, 93(5), 402408. doi:10.1038/clpt.2013.2.
Hicks, JK, Sangkuhl, K, Swen, JJ, et al. (2016). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther, 102(1), 3744. doi:10.1002/cpt.597.
Hiemke, C, Bergemann, N, Clement, HW, et al. (2018). Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 51(1–2), e1. doi:10.1055/s-0037-1600991.
Hillhouse, TM, Porter, JH (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol, 23(1), 121. doi:10.1037/a0038550.
Hisaka, A, Ohno, Y, Yamamoto, T, Suzuki, H (2010). Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther, 125(2), 230248. doi:10.1016/j.pharmthera.2009.10.011.
Hjorthoj, C, Ostergaard, MLD, Benros, ME, et al. (2015). Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry, 2(9), 801808. doi:10.1016/S2215-0366(15)00207-2.
Hoffman, SM, Nelson, DR, Keeney, DS (2001). Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics, 11(8), 687698.
Hofmann, MH, Blievernicht, JK, Klein, K, et al. (2008). Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther, 325(1), 284292. doi:10.1124/jpet.107.133306.
Holstein, A, Plaschke, A, Ptak, M, et al. (2005). Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol, 60(1), 103106. doi:10.1111/j.1365-2125.2005.02379.x.
Hoosain, FG, Choonara, YE, Tomar, LK, et al. (2015). Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int, 2015, 484963. doi:10.1155/2015/484963.
Horrigan, JP, Barnhill, LJ (1994). Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiatry, 33(7), 10601061. doi:10.1097/00004583-199409000-00022.
Hu, GX, Dai, DP, Wang, H, et al. (2017). Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics, 18(4), 369379. doi:10.2217/pgs-2016-0179.
Hu, Y, Oscarson, M, Johansson, I, et al. (1997). Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol, 51(3), 370376.
Huang, C, Kurland, AA (1964). Perphenazine (trilafon) metabolism in psychotic patients. Arch Gen Psychiatry, 10(6), 639646.
Huezo-Diaz, P, Perroud, N, Spencer, EP, et al. (2012). CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol, 26(3), 398407. doi:10.1177/0269881111414451.
Imaoka, S, Funae, Y (1990). Purification and characterization of rat pulmonary cytochrome P-450. J Biochem, 108(1), 3336.
Ingelman-Sundberg, M (2004a). Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol, 369(1), 89104. doi:10.1007/s00210-003-0819-z.
Ingelman-Sundberg, M (2004b). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci, 25(4), 193200. doi:10.1016/j.tips.2004.02.007.
Ishii, Y, Iwanaga, M, Nishimura, Y, et al. (2007). Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metab Pharmacokinet, 22(5), 367376.
Ishikawa, T (1992). The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci, 17(11), 463468.
Jackson, MR, Craft, JA, Burchell, B (1987). Nucleotide and deduced amino acid sequence of human liver microsomal epoxide hydrolase. Nucleic Acids Res, 15(17), 7188.
Jančová, P, Šiller, M (2012). Phase II drug metabolism. In Paxton, J, ed., Topics on Drug Metabolism. Croatia: InTech, pp. 3560.
Jann, MW, Cohen, LJ (2000). The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact, 16(1), 3967.
Jaquenoud Sirot, E, Knezevic, B, Morena, GP, et al. (2009). ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol, 29(4), 319326. doi:10.1097/JCP.0b013e3181acc372.
Jerling, M, Dahl, ML, Aberg-Wistedt, A, et al. (1996). The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther, 59(4), 423428. doi:10.1016/S0009-9236(96)90111-3.
Jiang, Z, Dalton, TP, Jin, L, et al. (2005). Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat, 25(2), 196206. doi:10.1002/humu.20134.
Johannessen, SI, Landmark, CJ (2010). Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol, 8(3), 254267. doi:10.2174/157015910792246254.
Johansson, I, Ingelman-Sundberg, M (2011). Genetic polymorphism and toxicology – with emphasis on cytochrome p450. Toxicol Sci, 120(1), 113. doi:10.1093/toxsci/kfq374.
Johansson, I, Lundqvist, E, Bertilsson, L, et al. (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A, 90(24), 1182511829.
Johansson, I, Oscarson, M, Yue, QY, et al. (1994). Genetic-analysis of the Chinese cytochrome P4502d locus – characterization of variant Cyp2d6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol, 46(3), 452459.
Johne, A, Brockmoller, J, Bauer, S, et al. (1999). Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther, 66(4), 338345. doi:10.1053/cp.1999.v66.a101944.
Johnstone, E, Benowitz, N, Cargill, A, et al. (2006). Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther, 80(4), 319330. doi:10.1016/j.clpt.2006.06.011.
Jornil, J, Jensen, KG, Larsen, F, Linnet, K (2010). Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos, 38(3), 376385. doi:10.1124/dmd.109.030551.
Jung, F, Richardson, TH, Raucy, JL, Johnson, EF (1997). Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos, 25(2), 133139.
Jurica, J, Sulcova, A (2012). Determination of cytochrome P450 metabolic activity using selective markers. In Paxton, J, ed., Topics on Drug Metabolism. Croatia: InTech, pp. 191220.
Kagimoto, M, Heim, M, Kagimoto, K, Zeugin, T, Meyer, UA (1990). Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem, 265(28), 1720917214.
Kalow, W, Tyndale, R (1992). Debrisoquine/sparteine monooxygenase and other P450s in brain. In Kalow, W, ed., Pharmacogenetics of Drug Metabolism. Oxford: Pergamon Press, pp. 649656.
Kasperaviciūte, D, Sisodiya, SM (2009). Epilepsy pharmacogenetics. Pharmacogenomics, 10(5), 817836. doi:10.2217/pgs.09.34.
Kertesz, SG, Pletcher, MJ, Safford, M, et al. (2007). Illicit drug use in young adults and subsequent decline in general health: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Drug Alcohol Depend, 88(2–3), 224233. doi:10.1016/j.drugalcdep.2006.10.017.
Khan, KK, He, YQ, Domanski, TL, Halpert, JR (2002). Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol, 61(3), 495506.
Kim, HY, Korade, Z, Tallman, KA, et al. (2016). Inhibitors of 7-dehydrocholesterol reductase: screening of a collection of pharmacologically active compounds in Neuro2a cells. Chem Res Toxicol, 29(5), 892900. doi:10.1021/acs.chemrestox.6b00054.
King, J, Aberg, JA (2008). Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS, 22(14), 17091717. doi:10.1097/QAD.0b013e32830163ad.
Kirchheiner, J, Brøsen, K, Dahl, ML, et al. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand, 104(3), 173192.
Kirchheiner, J, Klein, C, Meineke, I, et al. (2003). Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics, 13(10), 619626. doi:10.1097/01.fpc.0000054125.14659.d0.
Kirchheiner, J, Nickchen, K, Bauer, M, et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry, 9(5), 442473. doi:10.1038/sj.mp.4001494.
Kirschbaum, KM, Müller, MJ, Malevani, J, et al. (2008). Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry, 9(3), 212218. doi:10.1080/15622970701361255.
Klaassen, CD, Slitt, AL (2005). Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab, 6(4), 309328.
Klees, TM, Sheffels, P, Dale, O, Kharasch, ED (2005). Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos, 33(3), 303311. doi:10.1124/dmd.104.002709.
Klein, K, Lang, T, Saussele, T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics, 15(12), 861873.
Klotz, U (2006). Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther, 44(7), 297302.
Klotz, U (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev, 41(2), 6776.
Knutti, R, Rothweiler, H, Schlatter, C (1981). Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol, 21(2), 121126.
Kobayashi, K, Chiba, K, Yagi, T, et al. (1997). Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther, 280(2), 927933.
Kolars, JC, Lown, KS, Schmiedlin-Ren, P, et al. (1994). CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4(5), 247259.
Komatsu, T, Yamazaki, H, Shimada, N, Nakajima, M, Yokoi, T. (2000). Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos, 28(12), 14571463.
Koola, MM, Tsapakis, EM, Wright, P, et al. (2014). Association of tardive dyskinesia with variation in CYP2D6: is there a role for active metabolites? J Psychopharmacol, 28(7), 665670. doi:10.1177/0269881114523861.
Korade, Z, Xu, L, Shelton, R, Porter, NA (2010). Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome. J Lipid Res, 51(11), 32593269.
Korade, Z, Kim, HY, Tallman, KA, et al. (2016). The effect of small molecules on sterol homeostasis: measuring 7-dehydrocholesterol in Dhcr7-deficient Neuro2a cells and human fibroblasts. J Med Chem, 59(3), 11021115. doi:10.1021/acs.jmedchem.5b01696.
Korzekwa, KR, Krishnamachary, N, Shou, M, et al. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37(12), 41374147. doi:10.1021/bi9715627.
Koskinen, J, Lohonen, J, Koponen, H, Isohanni, M, Miettunen, J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull, 36(6), 11151130. doi:10.1093/schbul/sbp031.
Koukouritaki, SB, Manro, JR, Marsh, SA, et al. (2004). Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther, 308(3), 965974. doi:10.1124/jpet.103.060137.
Koyama, E, Tanaka, T, Chiba, K, et al. (1996). Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4’-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol, 16(4), 286293.
Koyama, E, Chiba, K, Tani, M, Ishizaki, T (1997). Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther, 281(3), 11991210.
Krueger, SK, Williams, DE (2005). Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther, 106(3), 357387. doi:10.1016/j.pharmthera.2005.01.001.
Krueger, SK, Williams, DE, Yueh, MF, et al. (2002). Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab Rev, 34(3), 523532. doi:10.1081/DMR-120005653.
Kubo, M, Koue, T, Inaba, A, et al. (2005). Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet, 20(1), 5564.
Kubo, M, Koue, T, Maune, H, Fukuda, T, Azuma, J (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet, 22(5), 358366.
Kuehl, P, Zhang, J, Lin, Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 27(4), 383391. doi:10.1038/86882.
Kuhn, R (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry, 115(5), 459464. doi:10.1176/ajp.115.5.459.
Kumana, CR, Lauder, IJ, Chan, M, Ko, W, Lin, HJ (1987). Differences in diazepam pharmacokinetics in Chinese and white Caucasians – relation to body lipid stores. Eur J Clin Pharmacol, 32(2), 211215.
Kuzman, MR, Medved, V, Bozina, N, et al. (2011). Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J, 11(1), 3544. doi:10.1038/tpj.2010.7.
Laika, B, Leucht, S, Heres, S, Schneider, H, Steimer, W (2010). Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J, 10(1), 2029. doi:10.1038/tpj.2009.32.
Laird, B, Colvin, L, Fallon, M (2008). Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer, 44(8), 10781082. doi:10.1016/j.ejca.2008.03.022.
Lam, YW, Gaedigk, A, Ereshefsky, L, Alfaro, CL, Simpson, J (2002). CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy, 22(8), 10011006.
Lamba, J, Schuetz, E (2008). Genetic variants of xenobiotic receptors and their implications in drug metabolism and pharmacogenetics. In Xie, W, ed., Nuclear Receptors in Drug Metabolism. Hoboken: John Wiley & Sons, pp. 241273.
Lamba, JK, Lin, YS, Schuetz, EG, Thummel, KE (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev, 54(10), 12711294.
Lamba, J, Lamba, V, Schuetz, E (2005). Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab, 6(4), 369383.
Lamba, V, Lamba, J, Yasuda, K, et al. (2003). Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther, 307(3), 906922. doi:10.1124/jpet.103.054866.
Lampe, JW, King, IB, Li, S, et al. (2000). Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis, 21(6), 11571162.
Lang, T, Klein, K, Fischer, J, et al. (2001). Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11(5), 399415.
Lang, T, Klein, K, Richter, T, et al. (2004). Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther, 311(1), 3443. doi:10.1124/jpet.104.068973.
Le Marchand, L, Franke, AA, Custer, L, Wilkens, LR, Cooney, RV (1997). Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics, 7(1), 1119.
Leclerc, J, Courcot-Ngoubo Ngangue, E, Cauffiez, C, et al. (2011). Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie, 93(6), 10121027. doi:10.1016/j.biochi.2011.02.012.
Lee, CR, Goldstein, JA, Pieper, JA (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12(3), 251263.
Li, F, Zhang, A, Shi, Y, Ma, Y, Du, Y (2015). 1alpha,25-Dihydroxyvitamin D3 prevents the differentiation of human lung fibroblasts via microRNA-27b targeting the vitamin D receptor. Int J Mol Med, 36(4), 967974. doi:10.3892/ijmm.2015.2318.
Linnet, K, Wiborg, O (1996). Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther, 60(1), 4147. doi:10.1016/S0009-9236(96)90165-4.
Liston, HL, DeVane, CL, Boulton, DW, et al. (2002). Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol, 22(2), 169173.
Liu, HQ, Zhang, CP, Zhang, CZ, Liu, XC, Liu, ZJ (2015). Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis. Biomed Res Int, 2015, 564149. doi:10.1155/2015/564149.
Lobo, ED, Bergstrom, RF, Reddy, S, et al. (2008). In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet, 47(3), 191202. doi:10.2165/00003088-200847030-00005.
Lodhi, RJ, Wang, Y, Rossolatos, D, et al. (2017). Investigation of the COMT Val158Met variant association with age of onset of psychosis, adjusting for cannabis use. Brain Behav, 7(11), e00850. doi:10.1002/brb3.850.
Lomri, N, Yang, Z, Cashman, JR (1993). Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. Chem Res Toxicol, 6(4), 425429.
Löscher, W, Klotz, U, Zimprich, F, Schmidt, D (2009). The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 50(1), 123. doi:10.1111/j.1528-1167.2008.01716.x.
Lubomirov, R, Colombo, S, di Iulio, J, et al.; Swiss, HIV Consortium Study (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis, 203(2), 246257. doi:10.1093/infdis/jiq043.
Mackay, RJ, McEntyre, CJ, Henderson, C, Lever, M, George, PM (2011). Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clin Biochem Rev, 32(1), 3343.
Madsen, H, Hansen, TS, Brøsen, K (1996). Imipramine metabolism in relation to the sparteine oxidation polymorphism – a family study. Pharmacogenetics, 6(6), 513519.
Mahgoub, A, Idle, JR, Dring, LG, Lancaster, R, Smith, RL (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet, 2(8038), 584586.
Mailman, RB, Murthy, V (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des, 16(5), 488501.
Majewska, MD, Mienville, JM, Vicini, S (1988). Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neurosci Lett, 90(3), 279284.
Mallikaarjun, S, Kane, JM, Bricmont, P, et al. (2013). Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res, 150(1), 281288. doi:10.1016/j.schres.2013.06.041.
Mamiya, K, Ieiri, I, Miyahara, S, et al. (1998a). Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics, 8(1), 8790.
Mamiya, K, Ieiri, I, Shimamoto, J, et al. (1998b). The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia, 39(12), 13171323.
Mammen, G, Rueda, S, Roerecke, M, et al. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry, 79(4), pii: 17r11839. doi:10.4088/JCP.17r11839.
Manrique-Garcia, E, de Leon, AP, Dalman, C, Andreasson, S, Allebeck, P (2016). Cannabis, psychosis, and mortality: a cohort study of 50,373 Swedish men. Am J Psychiatry, 173(8), 790798. doi:10.1176/appi.ajp.2016.14050637.
Masimirembwa, C, Persson, I, Bertilsson, L, Hasler, J, Ingelman-Sundberg, M (1996). A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol, 42(6), 713719.
Massoulié, J, Pezzementi, L, Bon, S, Krejci, E, Vallette, FM (1993). Molecular and cellular biology of cholinesterases. Prog Neurobiol, 41(1), 3191.
McConnell, HW, Mitchell, SC, Smith, RL, Brewster, M (1997). Trimethylaminuria associated with seizures and behavioural disturbance: a case report. Seizure, 6(4), 317321.
McManus, ME, Burgess, WM, Veronese, ME, et al. (1990). Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res, 50(11), 33673376.
Michaels, S, Wang, MZ (2014). The revised human liver cytochrome P450 ‘Pie’: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos, 42(8), 12411251. doi:10.1124/dmd.114.058040.
Mittal, B, Tulsyan, S, Kumar, S, Mittal, RD, Agarwal, G (2015). Cytochrome P450 in cancer susceptibility and treatment. Adv Clin Chem, 71, 77139.
Morita, S, Shimoda, K, Someya, T, et al. (2000). Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol, 20(2), 141149.
Motika, MS, Zhang, J, Cashman, JR (2007). Flavin-containing monooxygenase 3 and human disease. Expert Opin Drug Metab Toxicol, 3(6), 831845. doi:10.1517/17425255.3.6.831.
Murai, K, Yamazaki, H, Nakagawa, K, Kawai, R, Kamataki, T (2009). Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica, 39(11), 795802. doi:10.3109/00498250903171395.
Murray, GI, Melvin, WT, Greenlee, WF, Burke, MD (2001). Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol, 41, 297316. doi:10.1146/annurev.pharmtox.41.1.297.
Murru, A, Popovic, D, Pacchiarotti, I, et al. (2015). Management of adverse effects of mood stabilizers. Curr Psychiatry Rep, 17(8), 603. doi:10.1007/s11920-015-0603-z.
Mushiroda, T, Takahashi, Y, Onuma, T, et al. (2018). Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol, 75(7), 842849. doi:10.1001/jamaneurol.2018.0278.
Mwenifumbo, JC, Sellers, EM, Tyndale, RF (2007). Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend, 89(1), 2433. doi:10.1016/j.drugalcdep.2006.11.012.
Nagaoka, R, Iwasaki, T, Rokutanda, N, et al. (2006). Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine, 30(3), 261268. doi:10.1007/s12020-006-0003-6.
Nakajima, M, Yokoi, T, Mizutani, M, et al. (1999). Genetic polymorphism in the 5’-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem, 125(4), 803808.
Nakajima, M, Fukami, T, Yamanaka, H, et al. (2006). Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther, 80(3), 282297. doi:10.1016/j.clpt.2006.05.012.
Nakajima, Y, Saito, Y, Shiseki, K, et al. (2005). Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol, 61(1), 2534. doi:10.1007/s00228-004-0878-1.
Naraharisetti, SB, Lin, YS, Rieder, MJ, et al. (2010). Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos, 38(6), 889893. doi:10.1124/dmd.109.031542.
Nebert, DW, Russell, DW (2002). Clinical importance of the cytochromes P450. Lancet, 360(9340), 11551162. doi:10.1016/S0140-6736(02)11203-7.
Nelson, DR, Zeldin, DC, Hoffman, SM, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14(1), 118.
Niwa, T, Shizuku, M, Yamano, K (2017). Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6. Arch Biochem Biophys, 620, 2327. doi:10.1016/j.abb.2017.03.009.
Niwa, T, Yanai, M, Matsumoto, M, Shizuku, M (2018). Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-tyramine. J Pharm Pharm Sci, 21(1), 135142. doi:10.18433/jpps29673.
Niznik, HB, Tyndale, RF, Sallee, FR, et al. (1990). The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys, 276(2), 424432.
Nordin, C, Siwers, B, Benitez, J, Bertilsson, L (1985). Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients – relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol, 19(6), 832835.
O’Brien, FE, Dinan, TG, Griffin, BT, Cryan, JF (2012). Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol, 165(2), 289312. doi:10.1111/j.1476-5381.2011.01557.x.
Oesch, F, Raphael, D, Schwind, H, Glatt, HR (1977). Species differences in activating and inactivating enzymes related to the control of mutagenic metabolites. Arch Toxicol, 39(1–2), 97108.
Ohmori, O, Suzuki, T, Kojima, H, et al. (1998). Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res, 32(2), 107113.
Ohtsuki, S, Schaefer, O, Kawakami, H, et al. (2012). Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos, 40(1), 8392. doi:10.1124/dmd.111.042259.
Okubo, M, Murayama, N, Shimizu, M, et al. (2013). CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci, 38(3), 349354.
Olesen, OV, Linnet, K (2000). Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol, 50(6), 563571.
Oscarson, M, Hidestrand, M, Johansson, I, Ingelman-Sundberg, M (1997). A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol, 52(6), 10341040.
Oscarson, M, Gullsten, H, Rautio, A, et al. (1998). Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett, 438(3), 201205.
Ouzzine, M, Magdalou, J, Burchell, B, Fournel-Gigleux, S (1999). An internal signal sequence mediates the targeting and retention of the human UDP-glucuronosyltransferase 1A6 to the endoplasmic reticulum. J Biol Chem, 274(44), 3140131409.
Ouzzine, M, Gulberti, S, Ramalanjaona, N, Magdalou, J, Fournel-Gigleux, S (2014). The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication. Front Cell Neurosci, 8, 349. doi:10.3389/fncel.2014.00349.
Owens, MJ (1996). Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety, 4(4), 153159. doi:10.1002/(SICI)1520-6394(1996)4:4<53::aid-da1>3.0.CO;2-G.
Owens, MJ, Morgan, WN, Plott, SJ, Nemeroff, CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther, 283(3), 13051322.
Owens, MJ, Knight, DL, Nemeroff, CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry, 50(5), 345350.
Ozdemir, V, Naranjo, CA, Herrmann, N, et al. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther, 62(3), 334347. doi:10.1016/S0009-9236(97)90037-0.
Ozdemir, V, Bertilsson, L, Miura, J, et al. (2007). CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics, 17(5), 339347. doi:10.1097/FPC.0b013e32801a3c10.
Pacifici, GM, Bencini, C, Rane, A (1986). Acetyltransferase in humans: development and tissue distribution. Pharmacology, 32(5), 283291. doi:10.1159/000138181.
Palleria, C, Di Paolo, A, Giofrè, C, et al. (2013). Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci, 18(7), 601610.
Pan, YZ, Gao, W, Yu, AM (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos, 37(10), 21122117. doi:10.1124/dmd.109.027680.
Pariente-Khayat, A, Pons, G, Rey, E, et al. (1991). Caffeine acetylator phenotyping during maturation in infants. Pediatr Res, 29(5), 492495. doi:10.1203/00006450-199105010-00015.
Parker, AC, Pritchard, P, Preston, T, Choonara, I (1998). Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol, 45(2), 176178.
Pelkonen, O, Rautio, A, Raunio, H, Pasanen, M (2000). CYP2A6: a human coumarin 7-hydroxylase. Toxicology, 144(1), 139147.
Pelkonen, O, Turpeinen, M, Hakkola, J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol, 82(10), 667715. doi:10.1007/s00204-008-0332-8.
Perry, PJ, Pfohl, BM, Holstad, SG (1987). The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet, 13(6), 381392. doi:10.2165/00003088-198713060-00003.
Persson, I, Aklillu, E, Rodrigues, F, Bertilsson, L, Ingelman-Sundberg, M (1996). S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics, 6(6), 521526.
Phillips, EJ, Sukasem, C, Whirl-Carrillo, M, et al. (2018). Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther, 103(4), 574581. doi:10.1002/cpt.1004.
Phillips, IR, Shephard, EA (2017). Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol, 13(2), 167181. doi:10.1080/17425255.2017.1239718.
Piatkov, I, Caetano, D, Assur, Y, et al. (2017). ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med, 10, 235242. doi:10.2147/PGPM.S142314.
Pinto, N, Dolan, ME (2011). Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab, 12(5), 487497.
Pisanu, C, Melis, C, Squassina, A (2016). Lithium pharmacogenetics: where do we stand? Drug Dev Res, 77(7), 368373. doi:10.1002/ddr.21341.
Pollock, BG, Mulsant, BH, Sweet, RA, et al. (1995). Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull, 31(2), 327331.
Preskorn, SH (2003). Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part I). J Psychiatr Pract, 9(2), 150158.
Preskorn, SH (2012). Changes in the product label for pimozide illustrate both the promises and the challenges of personalized medicine. J Clin Psychiatry, 73(9), 11911193. doi:10.4088/JCP.12com07963.
Preskorn, SH (2013). Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug’s effect. J Psychiatr Pract, 19(5), 397405. doi:10.1097/01.pra.0000435038.91049.cb.
Preskorn, SH, Jerkovich, GS (1990). Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol, 10(2), 8895.
Pringsheim, T, Marras, C (2009). Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev, (2), CD006996. doi:10.1002/14651858.CD006996.pub2.
Puangpetch, A, Vanwong, N, Nuntamool, N, et al. (2016). CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med, 9, 131147. doi:10.2147/PGPM.S107772.
Puranik, YG, Birnbaum, AK, Marino, SE, et al. (2013). Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics, 14(1), 3545. doi:10.2217/pgs.12.180.
Qin, XP, Xie, HG, Wang, W, et al. (1999). Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther, 66(6), 642646. doi:10.1016/S0009-9236(99)90075-9.
Raimundo, S, Fischer, J, Eichelbaum, M, et al. (2000). Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics, 10(7), 577581.
Raimundo, S, Toscano, C, Klein, K, et al. (2004). A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther, 76(2), 128138. doi:10.1016/j.clpt.2004.04.009.
Raskin, A, Crook, TH (1975). Antidepressants in black and white inpatients. Differential response to a controlled trial of chlorpromazine and imipramine. Arch Gen Psychiatry, 32(5), 643649.
Rau, T, Diepenbruck, S, Diepenbruck, I, Eschenhagen, T (2006). The 2988G>A polymorphism affects splicing of a CYP2D6 minigene. Clin Pharmacol Ther, 80(5), 555558; author reply 558560. doi:10.1016/j.clpt.2006.08.008.
Raunio, H, Rahnasto-Rilla, M (2012). CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact, 27(2), 7388. doi:10.1515/dmdi-2012-0001.
Reale, M, Costantini, E, Di Nicola, M, et al. (2018). Butyrylcholinesterase and acetylcholinesterase polymorphisms in Multiple sclerosis patients: implication in peripheral inflammation. Sci Rep, 8(1), 1319. doi:10.1038/s41598-018-19701-7.
Relling, MV, Klein, TE (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther, 89(3), 464467. doi:10.1038/clpt.2010.279.
Relling, MV, Gardner, EE, Sandborn, WJ, et al.; Clinical Pharmacogenetics Implementation, Consortium (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther, 89(3), 387391. doi:10.1038/clpt.2010.320.
Rettie, AE, Jones, JP (2005). Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol, 45, 477494. doi:10.1146/annurev.pharmtox.45.120403.095821.
Ribaudo, HJ, Haas, DW, Tierney, C, et al.; Adult AIDS Clinical Trials Group Study (2006). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis, 42(3), 401407. doi:10.1086/499364.
Riches, Z, Stanley, EL, Bloomer, JC, Coughtrie, MW (2009). Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT ‘pie’. Drug Metab Dispos, 37(11), 22552261. doi:10.1124/dmd.109.028399.
Rietveld, EC, Broekman, MM, Houben, JJ, Eskes, TK, van Rossum, JM (1984). Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. Eur J Clin Pharmacol, 26(3), 371373.
Riordan, JR, Deuchars, K, Kartner, N, et al. (1985). Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 316(6031), 817819.
Rizzo, N, Hispard, E, Dolbeault, S, et al. (1997). Impact of long-term ethanol consumption on CYP1A2 activity. Clin Pharmacol Ther, 62(5), 505509. doi:10.1016/S0009-9236(97)90045-X.
Robbins, MG, Andersen, G, Somoza, V, et al. (2011). Heat treatment of Brussels sprouts retains their ability to induce detoxification enzyme expression in vitro and in vivo. J Food Sci, 76(3), C454C461. doi:10.1111/j.1750-3841.2011.02105.x.
Roberts, RL, Mulder, RT, Joyce, PR, Luty, SE, Kennedy, MA (2004). No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol, 19(1), 1723. doi:10.1002/hup.539.
Rochat, B, Amey, M, Gillet, M, Meyer, UA, Baumann, P (1997). Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics, 7(1), 110.
Rogers, HL, Bhattaram, A, Zineh, I, et al. (2012). CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration’s new dosing recommendations. J Clin Psychiatry, 73(9), 11871190. doi:10.4088/JCP.11m07572.
Roh, HK, Dahl, ML, Tybring, G, et al. (1996). CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics, 6(6), 547551.
Roninson, IB, Chin, JE, Choi, KG, et al. (1986). Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A, 83(12), 45384542.
Rost, KL, Brosicke, H, Heinemeyer, G, Roots, I (1994). Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology, 20(5), 12041212.
Rotger, M, Tegude, H, Colombo, S, et al. (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther, 81(4), 557566. doi:10.1038/sj.clpt.6100072.
Rothman, RB, Baumann, MH, Dersch, CM, et al. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39(1), 3241. doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.CO;2-3.
Rudberg, I, Mohebi, B, Hermann, M, Refsum, H, Molden, E (2007). Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther, 83(2), 322327.
Rudorfer, MV, Robins, E (1982). Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry, 43(11), 457460.
Saeed, LH, Mayet, AY (2013). Genotype-phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci, 10(11), 14971502. doi:10.7150/ijms.6795.
Saez-Valero, J, Sberna, G, McLean, CA, Small, DH (1999). Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer’s disease. J Neurochem, 72(4), 16001608.
Sakuyama, K, Sasaki, T, Ujiie, S, et al. (2008). Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57). Drug Metab Dispos, 36(12), 24602467. doi:10.1124/dmd.108.023242.
Sanchez, C, Hyttel, J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol, 19(4), 467489.
Saruwatari, J, Ishitsu, T, Nakagawa, K (2010). Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharmaceuticals (Basel), 3(8), 27092732. doi:10.3390/ph3082709.
Schrag, ML, Wienkers, LC (2001). Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys, 391(1), 4955. doi:10.1006/abbi.2001.2401.
Sezutsu, H, Le Goff, G, Feyereisen, R (2013). Origins of P450 diversity. Philos Trans R Soc Lond B Biol Sci, 368(1612), 20120428.
Shimada, T, Yamazaki, H, Mimura, M, Inui, Y, Guengerich, FP (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 270(1), 414423.
Shin, JG, Park, JY, Kim, MJ, et al. (2002). Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos, 30(10), 11021107.
Siegle, I, Fritz, P, Eckhardt, K, Zanger, UM, Eichelbaum, M (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics, 11(3), 237245.
Sim, E, Westwood, I, Fullam, E (2007). Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol, 3(2), 169184. doi:10.1517/17425255.3.2.169.
Sim, E, Abuhammad, A, Ryan, A (2014). Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol, 171(11), 27052725. doi:10.1111/bph.12598.
Sim, SC, Risinger, C, Dahl, ML, et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther, 79(1), 103113. doi:10.1016/j.clpt.2005.10.002.
Sindrup, SH, Gram, LF, Brøsen, K, Eshoj, O, Mogensen, EF (1990). The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain, 42(2), 135144.
Sindrup, SH, Grodum, E, Gram, LF, Beck-Nielsen, H (1991). Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Ther Drug Monit, 13(5), 408414.
Sindrup, SH, Brøsen, K, Hansen, MG, et al. (1993). Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit, 15(1), 1117.
Singh, D, Cho, WC, Upadhyay, G (2015). Drug-induced liver toxicity and prevention by herbal antioxidants: an overview. Front Physiol, 6, 363. doi:10.3389/fphys.2015.00363.
Sjöqvist, F, Bertilsson, L (1984). Clinical pharmacology of antidepressant drugs: pharmacogenetics. Adv Biochem Psychopharmacol, 39, 359372.
Sjöqvist, F, Bertilsson, L, Asberg, M (1980). Monitoring tricyclic antidepressants. Ther Drug Monit, 2(1), 8593.
Skoda, RC, Demierre, A, McBride, OW, Gonzalez, FJ, Meyer, UA (1988). Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem, 263(3), 15491554.
Smith, RL (1986). Special Issue – Human Genetic Variations in Oxidative Drug-Metabolism – Introduction. Xenobiotica, 16(5), 361365. doi:10.3109/00498258609050244.
Sobanski, T, Bagli, M, Laux, G, Rao, ML (1997). Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry, 30(3), 106107. doi:10.1055/s-2007-979491.
Spina, E, Gitto, C, Avenoso, A, et al. (1997). Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol, 51(5), 395398.
Sproule, BA, Naranjo, CA, Brenmer, KE, Hassan, PC (1997). Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet, 33(6), 454471.
Staudinger, JL, Xu, C, Cui, YJ, Klaassen, CD (2010). Nuclear receptor-mediated regulation of carboxylesterase expression and activity. Expert Opin Drug Metab Toxicol, 6(3), 261271. doi:10.1517/17425250903483215.
Steimer, W, Zöpf, K, von Amelunxen, S, et al. (2004). Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem, 50(9), 16231633. doi:10.1373/clinchem.2003.030825.
Steimer, W, Zopf, K, von Amelunxen, S, et al. (2005). Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem, 51(2), 376385. doi:10.1373/clinchem.2004.041327.
Stern, RS, Divito, SJ (2017). Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology – thirty years of progress but still much to be done. J Invest Dermatol, 137(5), 10041008. doi:10.1016/j.jid.2017.01.003.
Sukasem, C, Chaichan, C, Nakkrut, T, et al. (2018). Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J Immunol Res, 2018, 2780272. doi:10.1155/2018/2780272.
Sweet, RA, Pollock, BG, Mulsant, BH, et al. (2000). Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol, 20(2), 181197.
Takagi, S, Nakajima, M, Mohri, T, Yokoi, T (2008). Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem, 283(15), 96749680. doi:10.1074/jbc.M709382200.
Takeuchi, F, McGinnis, R, Bourgeois, S, et al. (2009). A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 5(3), e1000433. doi:10.1371/journal.pgen.1000433.
Tang, MH, Pinsky, EG (2015). Mood and affect disorders. Pediatr Rev, 36(2), 5260; quiz 61. doi:10.1542/pir.36-2-52.
Tanner, JA, Prasad, B, Claw, KG, et al. (2017). Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and nongenetic factors. J Pharmacol Exp Ther, 360(1), 129139. doi:10.1124/jpet.116.237594.
Taskinen, J, Ethell, BT, Pihlavisto, P, et al. (2003). Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos, 31(9), 11871197. doi:10.1124/dmd.31.9.1187.
Teitelbaum, AM, Murphy, SE, Akk, G, et al. (2018). Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J, 18(1), 136143. doi:10.1038/tpj.2016.92.
Thomas, DR, Nelson, DR, Johnson, AM (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl), 93(2), 193200.
Tirona, RG, Lee, W, Leake, BF, et al. (2003). The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med, 9(2), 220224. doi:10.1038/nm815.
Tolson, AH, Wang, H (2010). Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev, 62(13), 12381249. doi:10.1016/j.addr.2010.08.006.
Toscano, C, Klein, K, Blievernicht, J, et al. (2006). Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics, 16(10), 755766. doi:10.1097/01.fpc.0000230112.96086.e0.
Tsuchiya, K, Gatanaga, H, Tachikawa, N, et al. (2004). Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun, 319(4), 13221326. doi:10.1016/j.bbrc.2004.05.116.
Tucker, GT, Houston, JB, Huang, SM (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – towards a consensus. Br J Clin Pharmacol, 52(1), 107117.
Tunbridge, EM, Harrison, PJ, Weinberger, DR (2006). Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry, 60(2), 141151. doi:10.1016/j.biopsych.2005.10.024.
Turpeinen, M, Tolonen, A, Chesne, C, et al. (2009). Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro, 23(4), 748753. doi:10.1016/j.tiv.2009.03.008.
Ueda, K, Clark, DP, Chen, CJ, et al. (1987). The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem, 262(2), 505508.
Ufer, M, Dilger, K, Leschhorn, L, et al. (2008). Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther, 84(1), 4346. doi:10.1038/sj.clpt.6100505.
Uhr, M, Tontsch, A, Namendorf, C, et al. (2008). Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57(2), 203209. doi:10.1016/j.neuron.2007.11.017.
US National Library of Medicine (2016). Abilify – aripiprazole tablet. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac (last accessed 5.12.18).
Václavíková, R, Hughes, DJ, Souček, P (2015). Microsomal epoxide hydrolase 1 (EPHX1): gene, structure, function, and role in human disease. Gene, 571(1), 18. doi:10.1016/j.gene.2015.07.071.
Vaishnavi, SN, Nemeroff, CB, Plott, SJ, et al. (2004). Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry, 55(3), 320322.
van der Weide, J, Steijns, LSW (1999). Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem, 36(6), 722729.
van der Weide, K, van der Weide, J (2015). The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol, 35(3), 228236. doi:10.1097/JCP.0000000000000319.
van Kempen, GMJ (1971). Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form. Psychopharmacology (Berl), 21(3), 283286.
Veeramah, KR, Thomas, MG, Weale, ME, et al. (2008). The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenet Genomics, 18(10), 877886. doi:10.1097/FPC.0b013e3283097311.
Vistisen, K, Poulsen, HE, Loft, S (1992). Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis, 13(9), 15611568.
von Moltke, LL, Greenblatt, DJ, Giancarlo, GM, et al. (2001). Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos, 29(8), 11021109.
von Richter, O, Burk, O, Fromm, MF, et al. (2004). Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther, 75(3), 172183. doi:10.1016/j.clpt.2003.10.008.
Wacher, VJ, Salphati, L, Benet, LZ (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev, 46(1–3), 89102.
Wang, D, Poi, MJ, Sun, X, et al. (2014). Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet, 23(1), 268278. doi:10.1093/hmg/ddt417.
Wang, D, Papp, AC, Sun, X (2015). Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet, 24(6), 15561562. doi:10.1093/hmg/ddu566.
Wang, H, Tompkins, LM (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab, 9(7), 598610.
Ward, BA, Gorski, JC, Jones, DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther, 306(1), 287300. doi:10.1124/jpet.103.049601.
Watson, CP (2000). The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain, 16(2 Suppl), S49S55.
Weinshilboum, RM, Otterness, DM, Szumlanski, CL (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol, 39, 1952. doi:10.1146/annurev.pharmtox.39.1.19.
Werk, AN, Lefeldt, S, Bruckmueller, H, et al. (2014). Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther, 95(4), 416422. doi:10.1038/clpt.2013.210.
Whetstine, JR, Yueh, MF, McCarver, DG, et al. (2000). Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol, 168(3), 216224. doi:10.1006/taap.2000.9050.
Windmill, KF, Gaedigk, A, Hall, PM, et al. (2000). Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci, 54(1), 1929.
Wong, DT, Horng, JS, Bymaster, FP, Hauser, KL, Molloy, BB (1974). A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci, 15(3), 471479.
Wong, DT, Bymaster, FP, Horng, JS, Molloy, BB (1975). A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. J Pharmacol Exp Ther, 193(3), 804811.
Woosley, RL, Chen, Y, Freiman, JP, Gillis, RA (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA, 269(12), 15321536.
Wu, B, Kulkarni, K, Basu, S, Zhang, S, Hu, M (2011). First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci, 100(9), 36553681. doi:10.1002/jps.22568.
Wu, FS, Gibbs, TT, Farb, DH (1991). Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol, 40(3), 333336.
Xie, Y, Ke, S, Ouyang, N, et al. (2009). Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem, 284(14), 91999205. doi:10.1074/jbc.M806193200.
Xu, C, Li, CY, Kong, AN (2005). Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res, 28(3), 249268.
Yamazaki, H, Inui, Y, Yun, C-H, Guengerich, FP, Shimada, T (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13(10), 17891794.
Yasukochi, Y, Satta, Y (2011). Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst, 86(2), 109116.
Yeung, CK, Lang, DH, Thummel, KE, Rettie, AE (2000). Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos, 28(9), 11071111.
Yimer, G, Amogne, W, Habtewold, A, et al. (2012). High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J, 12(6), 499506. doi:10.1038/tpj.2011.34.
Yokota, H, Tamura, S, Furuya, H, et al. (1993). Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3(5), 256263.
Yoshinari, K, Ueda, R, Kusano, K, et al. (2008). Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol, 76(1), 139145. doi:10.1016/j.bcp.2008.04.005.
Yu, AM, Idle, JR, Herraiz, T, Kupfer, A, Gonzalez, FJ (2003). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics, 13(6), 307319. doi:10.1097/01.fpc.0000054094.48725.b7.
Yue, Q-Y, Zhong, Z-H, Tybring, G, et al. (1998). Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther, 64(4), 384390.
Zanger, UM, Klein, K (2013). Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet, 4, 24.
Zanger, UM, Schwab, M (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138(1), 103141. doi:10.1016/j.pharmthera.2012.12.007.
Zanger, UM, Klein, K, Saussele, T, et al. (2007). Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics, 8(7), 743759. doi:10.2217/14622416.8.7.743.
Zhou, H, Josephy, PD, Kim, D, Guengerich, FP (2004). Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys, 422(1), 2330.
Ziegler, VE, Biggs, JT (1977). Tricyclic plasma levels. Effect of age, race, sex, and smoking. JAMA, 238(20), 21672169.
Ziegler, VE, Clayton, PJ, Biggs, JT (1977). A comparison study of amitriptyline and nortriptyline with plasma levels. Arch Gen Psychiatry, 34(5), 607612.
Zukunft, J, Lang, T, Richter, T, et al. (2005). A natural CYP2B6 TATA box polymorphism (-82T–> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol, 67(5), 17721782. doi:10.1124/mol.104.008086.